Additional related information may be found at: |
Neuropsychopharmacology: The Fifth Generation of Progress |
Dopaminergic Neuronal Systems in the Hypothalamus
Kenneth E. Moore and Keith J. Lookingland
The
roles of mesotelencephalic dopaminergic (DA) neuronal systems in regulating
basic neurological functions including integrative control of muscle movement
and affective behaviors have been established, and dysfunctions of these systems
have long been associated with neurological disease states including Parkinson’s
disease and schizophrenia. Therapeutic
strategies for treatment of these disorders typically utilize drugs that act
directly at specific DA receptors (or indirectly via increased DA release) to
activate receptors in the case of Parkinson's disease, or block receptors in
the case of schizophrenia. Since DA receptors participate in the regulation of other neurological
functions, these strategies may produce unwanted side effects, some of which
could mimic or disrupt non-targeted DA neuronal systems, including hypothalamic DA neurons.
In
a previous review published in 1987 (75) it was pointed out that there are differences
in the characteristics of neurons that comprise the various anatomically differentiated
DA neuronal systems in the mammalian brain. Indeed, evidence available at that time revealed
that neurochemical properties and responses to pharmacological and endocrinological
manipulations of the major ascending mesotelencephalic DA neurons are often
quite different from those DA neurons that originate in the diencephalon (i.e.,
those neurons identified as the A11, A12, A13
and A14 cell groups by the alphanumeric system of Dahlström and Fuxe
(12). This chapter provides an updated
review of these hypothalamic DA neurons.
Anatomical Overview
Details
of the anatomy of DA perikarya in the rat diencephalon are provided by Björklund
et al. (9) the location of their perikarya are depicted schematically in Fig.
1 . There are comparable numbers
of DA perikarya in the rat diencephalon (A11, A12, A13
and A14; 112) as in the substantia nigra (A8 and A9;
25, 26) or ventral tegmental area (A10; 25, 26), which are generally
considered to be the major loci of DA neurons in the brain. The most familiar hypothalamic DA neurons are
those that comprise the tuberoinfundibular (TI) DA system; perikarya of these
neurons (A12), which are located in the mediobasal hypothalamic arcuate
nucleus and adjacent periventricular nucleus, project to the external layer
of the median eminence (Fig. 2). Although TIDA neurons have been studied more extensively than other
DA neurons in the diencephalon they actually represent a minority of these DA
neurons (83). The majority of diencephalic
DA neurons are located in dorsal regions of the hypothalamus and ventral thalamus,
and the regions adjacent to the third ventricle. A small number of relatively large DA perikarya
(A11) are located in the posterior regions of the dorsal hypothalamus
and the periventricular gray of the central thalamus; axons from these neurons
project to the spinal cord. Due to the
paucity of information regarding the function of these diencephalospinal DA
neurons they will not be discussed in this chapter.
DA
perikarya identified as the A13 cell group are clustered in the rostral
regions of the medial zona incerta (MZI) and comprise the incertohypothalamic
(IH) DA system. Perikarya of these densely
packed DA neurons have extensive dendritic processes oriented in the ventral
plane which extend into the dorsomedial nucleus of the hypothalamus (102).
Early reports using histochemical fluorescence techniques suggested that
efferents of IHDA neurons project diffusely into the surrounding anterior, dorsomedial
and posterior regions of the hypothalamus (9).
The results of more recent anatomical (104) and neurochemical studies
(19) suggest, however, that IHDA neurons project much more extensively than
originally believed, innervating a variety of anatomically discrete brain regions
including the central nucleus of the amygdala, horizontal diagonal band of Broca
and hypothalamic paraventricular nucleus. The relative contribution of IHDA neurons to these regions varies;
i.e. DA terminals in the paraventricular nucleus originate exclusively from
IHDA neurons in the MZI, whereas IHDA neurons provide only a portion of the
DA innervation of the amygdala and horizontal
diagonal band of Broca (11). The majority
of DA input to these latter two regions originates from midbrain mesolimbic
DA neurons.
DA
neurons projecting to the posterior pituitary were reported initially to originate
from rostral A12 cells in the arcuate and periventricular nuclei;
accordingly, they were referred to as tuberohypophysial DA neurons.
A more recent study (28) revealed that DA neurons projecting to the intermediate
lobe of the pituitary originate from a subpopulation of A14 DA cells
in the periventricular nucleus (Fig. 3).
In this review DA neurons projecting to the intermediate lobe of the
pituitary will be identified as the periventricular-hypophysial dopaminergic
(PHDA) neurons, although in the majority of earlier references these neurons
are referred to as tuberohypophysial DA neurons.
The remaining A14 periventricular (PeV) DA neurons are believed
to project laterally into adjacent regions (e.g. medial preoptic area, anterior
hypothalamic area). Additional details
of the distribution of TIDA, IHDA, PHDA and PeVDA neurons can be found in the
following sections dealing with each of these neuronal systems.
Estimation of the Activity
of Hypothalamic DA Neurons
Only
a few investigators have attempted to directly measure the activity (or impulse
flow) of hypothalamic DA neurons. For
example, Sanghera (87) and Eaton and Moss (16) recorded electrical activity
from neurons in the MZI in response to a variety of pharmacological manipulations
using both in situ and in vitro slice preparations. Several laboratories have recorded electrical
activity in slices of the mediobasal hypothalamus, particularly from neurons
in the arcuate nucleus (51), but only a few studies determined unequivocally
that recordings were made from DA neurons (59, 109).
Alternatively,
investigators have employed a variety of neurochemical techniques to estimate
neurotransmitter release from hypothalamic DA neurons. The basis of these biochemical techniques is
that the release of DA is coupled to the rates of synthesis and metabolism of
DA in terminals and dendrites of DA neurons.
Procedures that increase or decrease neurotransmitter release from DA
neurons generally do not alter steady state concentrations of DA but produce
corresponding increases or decreases, respectively, in rates of synthesis, turnover
and metabolism of this amine. The utility
of various neurochemical procedures for estimating activity of hypothalamic
DA neurons has been discussed previously (75), and only reviewed briefly and
updated in this section.
A
number of investigators have employed in
vitro techniques to characterize neurochemical properties of TIDA and PHDA
neurons, but as this chapter will focus on the responses of hypothalamic DA
neuronal systems to physiological and pharmacological manipulations, discussions
will be limited to results obtained using in vivo techniques. Early
in vivo attempts to estimate the activity
of central catecholaminergic neurons involved studies that employed α-methyltyrosine,
an inhibitor of tyrosine hydroxylase (TH). Following administration of α-methyltyrosine
the concentrations of catecholamines are reduced in an exponential manner at
a rate that is proportional to the activity of the neurons that contain these
amines. The advantage of this technique
is that it permits concurrent estimation of DA and norepinephrine (NE) turnover
in the same hypothalamic brain region. There are, however, several disadvantages to
this procedure: 1) measurement of catecholamines must be made in groups of animals
killed immediately before and at least two different times after α-methyltyrosine
administration so as to assure that an exponential rate of decline has occured,
2) rapid measurements cannot be made which prohibits its use for short term
experimental manipulations, and 3) by virtue of its ability to block synthesis
α-methyltyrosine reduces catecholamine release which compromises neuronal
function. This is a problem when studying
TIDA neurons in that blockade of DA synthesis in TIDA neurons reduces DA release
into the hypophysial portal blood thereby removing DA inhibition of prolactin
secretion from the anterior pituitary. The
increase in circulating prolactin feeds back to increase activity of TIDA neurons.
The
rate of catecholamine synthesis is regulated at the step catalyzed by TH so
estimates of catecholaminergic activity can be obtained from measurements of
the activity of this enzyme. This can
be accomplished in vivo by administering
3-hydroxybenzylhydrazine (NSD 1015), an inhibitor of aromatic amino acid decarboxylase.
The concentration of 3,4-dihydroxyphenylalanine (DOPA) in brain tissue
is essentially zero because once it is synthesized from tyrosine it is immediately
decarboxylated to DA. Following the
administration of NSD 1015, DOPA accumulates in catecholaminergic nerve terminals
at a rate that is proportional to the activity of these neurons. The advantages of this procedure over the α-methyltyrosine
technique are that fewer measurements are needed (DOPA concentrations are so
low that 'zero-time' values are unnecessary), and they can be made over a shorter
time frame (i.e. as soon as 15 min after i.v. NSD 1015).
As with α-methyltyrosine, NSD 1015 disrupts catecholamine synthesis
and thereby alters the properties of the catecholaminergic neurons (e.g., NSD
1015, like α-methyltyrosine, increases plasma levels of prolactin).
Finally, DOPA accumulates in both DA and noradrenergic (NE) neurons after
the administration of NSD 1015. This
has little consequence when DOPA accumulation is measured in terminals of TIDA
and PHDA neurons in the median eminence or intermediate lobe of the pituitary
since the concentrations and turnover of DA greatly exceed those of NE.
In most hypothalamic regions, however, the concentrations of NE are greater
than DA so this procedure cannot be employed to estimate IHDA or PeVDA neuronal
activity.
In
brain regions containing a preponderance of DA over NE nerve terminals the concentrations
of 3,4-dihydroxyphenylacetic acid (DOPAC), a major metabolite of DA, reflect
the activity of DA neurons. It has been
shown empirically that increases and decreases in TIDA and PHDA neuronal activities
are accompanied by concurrent increases and decreases in DOPAC concentrations
in the median eminence and intermediate lobe of the pituitary, respectively
(53, 56). In contrast to techniques
that require administration of α-methyltyrosine or NSD 1015, no drug pretreatments
are required prior to the measurement of DOPAC concentrations; accordingly,
measurements can be made within minutes after initiating a manipulation.
In
the following discussions alterations in hypothalamic DA neuronal activity (i.e.
increases or decreases in neurotransmitter release) were estimated using one
or more of the neurochemical methods described above.
TUBEROINFUNDIBULAR
DOPAMINERGIC NEURONS
Anatomy
Perikarya
of TIDA (A12) neurons are located in the arcuate nucleus and adjacent
periventricular region of the rat mediobasal hypothalamus (12). Within the arcuate nucleus, two populations
of TH-containing neurons have been identified on the basis of their size and
location in either the dorsomedial or ventrolateral regions of this nucleus
(21). In the dorsomedial arcuate nucleus
and adjacent periventricular nucleus, relatively small DA perikarya have dendrites
oriented in the dorsoventral plane (102) and axons which project ventrally to
terminate in the external layer of the median eminence (9). High affinity DA uptake by TIDA neurons is
modest presumably due to less DA transporter protein and lower affinity of the
transporter for DA as compared with other central DA neurons with “classical”
post synaptic target receptors (75, 82). DA
released from terminals of TIDA neurons in the median eminence does not enter
a synapse but diffuses through fenestrated capillaries and is transported in
the hypophysial portal blood to the anterior pituitary where it activates D2
receptors on lactotrophs and tonically inhibits the secretion of prolactin from
these cells. TH-containing perikarya
in the ventrolateral arcuate nucleus are larger in size (21) with dendrites
oriented in the mediolateral plane (93) and axons that terminate in the lateral
portion of the median eminence (9). These neurons lack L-aromatic amino acid decarboxylase
(21, 70), and they do not express DA transporter protein mRNA as do the DA-containing
neurons in the dorsomedial portion of the arcuate nucleus (72).
"DOPAergic" neurons have also been identified in the ventrolateral
arcuate nuleus of the human brain, and although their functional significance
is unknown, it has been suggested that DOPA released from these neurons may
be decarboxylated to DA in the hypothalamic-pituitary vasculature (70).
TIDA
neurons in the dorsomedial arcuate nucleus also synthesize a number of neuromodulators/neurotransmitters
reported to have either inhibitory (GABA, galanin, enkephalin) or stimulatory
(neurotensin) effects on DA release from these neurons (21).
It has been postulated that these co-localized neurotransmitters may
be selectively synthesized and released under different physiological conditions
thereby modulating TIDA neuronal regulation of prolactin secretion, and the
responsiveness of these neurons to hormonal and neuronal feedback (71).
Neurochemistry
Each
of the neurochemical techniques described above in the Introduction has been
used effectively to estimate TIDA neuronal activity and have provided consistent
results. The terminal region of these
neurons, the median eminence, is well defined and relatively easy to dissect,
and the concentration and rate of turnover of DA are much higher than those
of NE so there is no difficulty in relating changes in DOPA accumulation or
DOPAC concentrations to TIDA activity (36, 56). The activity of these neurons has also been estimated from measurements
of the amount of DA released into hypophysial portal blood, but since this technique
involves use of anesthetized animals following radical surgery, there has been
little use of this technique in recent years. Neurochemical estimates of TIDA neuronal activity
have been correlated with reciprocal changes in circulating levels of prolactin.
One should be cognizant, however, that while the primary control of prolactin
secretion is exerted by the inhibitory actions of TIDA neurons, the secretion
of prolactin under some circumstances is influenced by prolactin-releasing factors.
Regulation of Activity
The
properties and responses of TIDA neurons differ in many respects from those
of other DA neuronal systems in the mammalian brain. Some of these differences were discussed in previous reviews (75);
additions to and updates of these differences are described below.
Sexual differences
There
are marked differences in the activities of TIDA neurons of male and female
rats. Although there is no sexual difference
in the density of TIDA nerve terminals (as reflected in the concentration of
DA in the median eminence), the rates of turnover, synthesis and metabolism
of DA in this region, and the concentration of DA in hypophysial portal blood
is 2-3 times higher in female than in male rats. TIDA neuronal activity is increased in the
male and decreased in the female after castration, and these effects are reversed
by replacement with testosterone (99) or with estrogen (101), respectively.
The ability of estrogen to increase TIDA neuronal activity in ovariectomized
rats is secondary to the ability of this hormone to increase circulating levels
of prolactin. The higher set point of TIDA neuronal activity
in females may be physiologically relevant for regulation of episodic hormone
secretion since prolactin surges which occur during the afternoon of proestrous,
pregnancy, and lactation are all associated with suppression of TIDA neuronal
activity and loss of DA inhibition of prolactin secretion. These topics have been reviewed elsewhere (75),
and will not be discussed here.
There
are also major sexual differences in the responses of TIDA neurons to a variety
of pharmacological and physiological manipulations. TIDA neurons in females are more responsive to the stimulating actions
of prolactin, the inhibitory effects of stress (57), and administration of kappa
opioid agonists (66) and the N-methyl-D-asparate receptor antagonist MK801 (105).
On the other hand, activation of TIDA neurons after administration of
bombesin (100) and a kappa opioid antagonist (66) is more pronounced in the
male. Additional details of the responses of TIDA
neurons in male and female rats are provided in the following sections which
describe the actions of individual drugs.
Effects of prolactin
Under
most physiological situations the activity of TIDA neurons is regulated, to
a large extent, by circulating levels of prolactin; other DA neurons are unresponsive
to this hormone. TIDA neuronal activity
is reduced during periods of hypoprolactinemia, such as that caused by hypophysectomy,
or the administration of DA agonists or prolactin antibody.
The reduction of TIDA neuronal activity is more pronounced in the female;
indeed, following several hours of low circulating levels of prolactin the activity
of these neurons in the female rat is equivalent to that seen in a male with
normal prolactin levels. On the other
hand, TIDA neuronal activity is increased during periods of hyperprolactinemia;
for example, following implantation of prolactin-secreting tumors, administration
of DA antagonists or estrogen, and the central or systemic administration of
prolactin. TIDA neurons in the female
rat are more sensitive and responsive to prolactin than they are in the male.
The
mechanism by which prolactin activates TIDA neurons has not been elucidated,
but the effects of this hormone are delayed and dependent upon protein synthesis
(46) suggesting that de novo synthesis
and release of a neuropeptide neurotransmitter may mediate the stimulatory actions
of prolactin on these neurons. A number of peptidergic receptors have been identified which could
mediate the delayed stimulatory effects of prolactin on TIDA neurons; among
these neurotensin, bombesin/gastrin-releasing peptide, and delta opioid receptors
are reasonable candidates (66, 77). Indeed,
the ability of a neurotensin antagonist to block prolactin-induced increases
in median eminence DOPAC concentrations (38) is consistent with a role for neurotensin
receptors in mediating the stimulatory effects of prolactin on TIDA neurons.
Putative afferent neurotransmitters
To
date, the majority of studies on TIDA neurons has focused on responses of these
neurons to changes in the hormonal milieu (e.g., prolactin, gonadal steroids;
75). It is apparent, however, that TIDA
neurons are also acutely responsive to afferent neuronal influences as evidenced
by the rapid responses of these neurons in female rats to stressful manipulations
and suckling, both of which promptly inhibit TIDA neuronal activity and thereby
increase plasma concentrations of prolactin (75). The neuronal circuits responsible for stress
or suckling-induced inhibition of TIDA neurons have not been well-defined, but
since the responses can be attenuated by antagonists of recognized neurotransmitters
(e.g., 5-hydroxytryptamine [5HT], acetylcholine), it is reasonable to assume
that neurons utilizing these transmitters are located somewhere in neuronal
circuits activated by stressful or suckling stimuli. A number of attempts have been made to employ
pharmacological techniques to uncover roles played by putative aminergic and
peptidergic neurotransmitters in regulating TIDA neuronal activity.
The following sections review some of the effects of putative neurotransmitters,
and their agonists and antagonists, on TIDA neuronal activity and secretion
of prolactin.
Drugs
which act as selective agonists or antagonists at mu, kappa or delta opioid
receptors produce characteristic patterns of responses of different DA neurons. Morphine and a variety of mu opioid agonists
increase the activity of the major mesotelencephalic DA neurons terminating
in the striatum and limbic forebrain regions (75), but inhibit TIDA neurons. Inhibition of TIDA neurons is responsible,
at least in part, for increased circulating levels of prolactin produced by
mu opioid agonists. The inhibitory action
of mu opioids on TIDA neurons appears due to their ability to hyperpolarize
these neurons by increasing potassium conductance (59).
Endogenous
mu opioids may play a role in the physiological regulation of TIDA neurons.
For example, in lactating, but not in male or estrous female rats, TIDA
neurons synthesize enkephalin (73). Enkephalin released from TIDA neurons during
lactation may act on mu opioid “autoreceptors” to inhibit DA release, and thereby
maintain high circulating levels of prolactin and milk production.
Drugs
that act at kappa opioid receptors also influence the activity of DA neurons,
but unlike mu opioid agonists (which depending on the neuronal system can increase
or decrease the activity of DA neurons), kappa agonists exert only inhibitory
actions. The degree of inhibition is
generally dependent upon the level of activity of the DA neurons at the time
the kappa agonist is administered. For
example, the kappa agonist U50,488 exerts only minimal inhibitory actions on
nigrostriatal, mesolimbic or TIDA neurons unless these neurons are activated
(64). U50,488 also reduces the high
level of activity of TIDA neurons in female rats, but is without effect in males
unless the latter animals are injected with prolactin or are orchidectomized
in order to activate their TIDA neurons (66). On the other hand, the selective kappa opioid
receptor antagonist norbinaltorphimine increases TIDA neuronal activity in male
but not in female rats suggesting that in males TIDA neurons are tonically inhibited
by the endogenous kappa opioid dynorphin. Consistent with this suggestion icv administration
of dynorphin antibodies to male rats increases the activity of TIDA neurons
(67).
There
have been few studies on the responses of hypothalamic DA neurons to drugs that
act at delta opioid receptors, but these drugs exert a pattern of effects that
is different from that of drugs acting on mu or kappa opioid receptors (68).
In male rats icv injection of [D-Pen2, D-Pen5]enkephalin,
an delta opioid receptor agonist, has no effect on nigrostriatal DA neurons,
but increases the activity of TIDA and mesolimbic DA neurons terminating in
nucleus accumbens. These effects are blocked by naltrindole, a
selective delta-opioid receptor antagonist, but this antagonist has no effect
per se
on DA neuronal systems.
Several
neuroactive peptides stimulate TIDA neurons; the most potent of these is bombesin.
Intracerebroventricular injection of this peptide into male rats at doses
as low as 1 ng causes a marked but relative short-lasting increase in TIDA neuronal
activity and a concomitant decrease in plasma concentrations of prolactin (65). Even at a higher doses this peptide is without
effect on activities of nigrostriatal or mesolimbic DA neurons. These stimulatory effects of bombesin are mimicked
by equimolar concentrations of gastrin-releasing peptide (GRP), a bombesin-like
peptide found in mammalian brain. The activation of TIDA neurons by bombesin and GRP are blocked by
a bombesin antagonist (MDL 101,562), but blockade of bombesin/GRP receptors
per se
is without effect, suggesting that under basal conditions these hypothalamic
DA neurons are not under tonic excitatory control of a bombesin-like peptide
(69). The stimulatory effect of bombesin
on TIDA neurons does not involve prolactin, but since the response is pronounced
in ovariectomized but not in gonadally-intact rats it would appear that the
stimulatory actions of bombesin in the female are reduced by estrogen (100).
Two
other peptides, αMSH and neurotensin, have been reported to activate TIDA
neurons. Central administration of αMSH
increases TIDA neuronal activity, and thereby reduces circulating concentrations
of prolactin (54). In contrast, αMSH
did not alter the activity of nigrostriatal or mesolimbic DA neurons.
Neurotensin is a peptide neurotransmitter located in neurons in the mediobasal
hypothalamus (40). Following icv administration of this peptide
TIDA neurons are activated (32), and neurotensin-induced activation of TIDA
neurons is related temporally with a decrease in plasma concentrations of prolactin
(77). Blockade of neurotensin receptors
prevents prolactin-induced increases in median eminence DOPAC concentrations
suggesting that endogenous neurotensin may play a role in prolactin feedback
activation of TIDA neurons (38).
Galanin
is a peptide which inhibits the activity of TIDA neurons in both female and
male rats (27). The effects of this
peptide on TIDA neurons is activity-dependent in that galanin only inhibits
the activity of TIDA neurons under stimulated conditions, but has no effect
on the basal activity of these neurons in either gender. This may represent an autoregulatory feedback mechanism by which
galanin co-localized and released from TIDA neurons regulates DA release.
A
number of amino acid-derived neurotransmitters presumably released from hypothalamic
interneurons are reported to have either stimulatory (e.g. excitatory amino
acids) or inhibitory (e.g. GABA) effects on the activity of TIDA neurons.
Glutamate acting at N-methyl-D-aspartate (NMDA) receptors tonically stimulates
the basal activity of TIDA neurons in female, but not male rats (105). This sexual difference in NMDA receptor-mediated regulation of TIDA
neuronal activity is likely due to estrogen-induced stimulation of glutamate
release by a prolactin-independent mechanism (105). In both genders, endogenous excitatory amino
acids acting at non-NMDA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) receptors tonically inhibit the basal activity of TIDA neurons (107)
by a mechanism involving GABAA receptors (106). Activation of GABAB receptors also
decreases the basal activity of TIDA neurons, but these neurons are not tonically
inhibited by endogenous GABA acting at GABAB receptors (31).
Psychoactive Drugs
Antipsychotics
Acute
administration of "classical" antipsychotics with D2 receptor
antagonistic properties (e.g., haloperidol) activates DA neurons that comprise
the mesotelencephalic systems, but has no direct action on TIDA neurons.
On the other hand, TIDA neurons are activated indirectly several hours
after administration of haloperidol and other D2 antagonists as
a result of their ability to increase circulating concentrations of prolactin
(75). By contrast, some atypical neuroleptics, exemplified
by clozapine, increase acutely TIDA neuronal activity (33). Although it has been proposed that the ability
of clozapine to activate TIDA neurons involves interactions with D1
DA receptors and/or neurotensin, the mechanism by which clozapine increases
the activity of these neurons remains to be elucidated. This action of clozapine may, however, be responsible for the drug's
brief elevation of plasma prolactin levels compared to the long duration of
its other effects. That is, the clozapine
increased release of DA from TIDA neurons may counteract the antagonistic actions
it has on release of prolactin from lactotrophs in the anterior pituitary.
DA agonists
By
activating autoreceptors and/or DA receptor-mediated neuronal feedback loops,
non-selective DA agonists (e.g., apomorphine, bromocriptine) reduce the activities
of those DA neurons that comprise the mesotelencephalic systems, but TIDA neurons
are unresponsive to the acute administration of these drugs (75).
Utilization of second generation agonists which differentiate between
the D1-like and D2-like subtype families of DA receptors
has revealed that TIDA neurons are also regulated by a DA receptor-mediated
mechanism which acts independently of prolactin (18).
Indeed, acute administration of DA agonists with preferential affinity
for the D2 family of DA receptors (i.e. quinpirole and quinelorane)
stimulates TIDA neurons (8, 18). This
stimulatory action of D2 agonists appears to occur via an afferent
neuronal mechanism involving, in part, disinhibition of tonically active dynorphinergic
interneurons (14). The inability of D2 receptor antagonists
to alter the activity of TIDA neurons per se suggests that there is little intrinsic endogenous DA agonism
of the D2 receptor under basal conditions (18). Conversely, acute administration of D1
agonists (e.g., SKF 38393,
CY 208-243) inhibits both “basal”
(15) and "activated" TIDA neurons (7). The opposing actions of stimulatory D2
and inhibitory D1 receptors could account for the net lack of effect
of mixed D1/D2 agonists on TIDA neurons.
Regulation of Gene Expression
Over
the last several years significant progress has been made regarding activity-dependent
regulation of gene expression in TIDA
neurons, especially with regard to the synthesis of catecholamine biosynthetic
enzymes. Of particular interest is the
role of immediate early genes in this process. Indeed, the relative number of
TIDA neuronal perikarya in the arcuate nucleus expressing Fos and related antigens
(FRA) including FOS, FRA1, FRA2 and FOSB (92) have collectively been correlated
with physiological and experimentally-induced changes in long-term gene expression
in these neurons (39, 49). Alterations
in FRA expression precede activity-dependent changes in expression of mRNA for
TH in TIDA neurons (39, 110), suggesting a role for these transcription factors
in the regulation of this rate-limiting enzyme in DA biosynthesis.
Details
of immediate early gene regulation of
TH gene expression in central catecholaminergic neurons have been reviewed recently
(48), and will only be briefly summarized here. Stimulation of FRA expression is generally
believed to involve ligand-mediated activation of membrane receptors located
on neuronal perikarya and/or dendrites which causes second messenger-mediated
Fos-related gene transcription, and synthesis of FRA mRNAs and proteins (41). In TH neurons, FRA proteins are translocated
to the nucleus where they form heterodimers with constititively expressed Jun-related
transcription factors that bind to the AP-1 promoter site on the TH gene and
facilitate transcription of TH mRNA (44). Thus, the presence of FRA proteins in nuclei of TH-containing neurons
represent a useful neurochemical marker of the responsiveness of discrete populations
of TIDA neurons.
There
are sexual differences in immediate early gene expression in TIDA neurons; i.e.,
the number of TIDA neurons expressing FRA is 2-3 times higher in females than
males in all but the most caudal region of the dorsomedial arcuate nucleus (16).
This suggests that comparable sexual differences in expression of TH
mRNA (3) and the neurochemical activity of TIDA neurons in the median eminence
(75) may be due, in part, to greater numbers of active TIDA neurons in females.
Sexual differences
in FRA expression in TIDA neurons are gonadal steroid-dependent; ovariectomy decreases, while orchidectomy increases
the number of TIDA neurons expressing FRA in the dorsomedial arcuate nucleus,
and these gonadectomy-induced effects are reversed by estrogen and testosterone,
respectively (16). Gonadal steroids also regulate the expression
of TH mRNA in TIDA neurons in both sexes. Estrogen suppresses expression of TH mRNA in ovariectomized females,
and this effect is reversed by progesterone (4). In males, orchidectomy increases the mass (or
amount) of TH in the median eminence, but has no effect on expression of TH
mRNA in TIDA neurons (1). These results
suggest that testosterone regulates the translation of TH mRNA, but not the
transcription of the TH gene. Since
many of these changes are disconcordant with the effects of estrogen and testosterone
on FRA expression in TIDA neurons (16), it is unlikely that immediate early
genes mediate gonadal steroid-induced changes in TH expression.
Several
lines of evidence indicate that prolactin-induced alterations in the activity
of TIDA neuron are accompanied by changes
in long-term gene expression that result in the ability of these neurons to
respond to chronic stimulation (74). Indeed, prolactin induces expression of mRNA for TH in TIDA neurons
in both females (2) and males (90), and “tonic” prolactin stimulation is necessary
for sustaining the higher basal TH mRNA expression in TIDA neurons in females
(2). Prolactin also increases the numbers of TIDA neurons expressing
FRA in the arcuate nucleus of female and male rats (37). Hyperprolactinemia
increases expression of nur/77 mRNA in chemically-unidentified neurons in regions
of the arcuate nucleus containing TIDA neurons (85), but the role of these (as
well as FRA) transcription factors in mediating prolactin-induced activation
of TH mRNA in TIDA neurons is currently unknown.
PERIVENTRICULAR-HYPOPHYSIAL
DOPAMINERGIC NEURONS
Anatomy
DA
axons terminating in the posterior pituitary were postulated initially to constitute
a distinct tuberohypophysial DA neuronal system originating from A12
perikarya located in the most rostral extent of the arcuate nucleus (9). A more recent study (28) revealed that DA neurons
terminating in the intermediate lobe of the posterior pituitary originate from
a sub-population of A14 DA neurons located in the periventricular
nucleus dorsal to the retrochiasmatic area of the anterior hypothalamus.
These PHDA neurons have dendrites oriented in the dorsoventral plane
(91) and axons that project ventrally through the internal layer of the median
eminence and pituitary stalk to terminate in close proximity to intermediate
lobe melanotrophs. DA released from PHDA neurons tonically inhibits
the secretion of the pro-opiomelanocortin-derived peptide hormones α-MSH
(28) and ß-endorphin from melanotrophs in the intermediate lobe.
In addition, DA neurons terminating in the intermediate lobe have been
implicated in the regulation of prolactin secretion (5).
PHDA
neurons also contain substances known to have both stimulatory (neurotensin;
43) and inhibitory (GABA; 103) effects on the release of DA in the intermediate
lobe. In addition, terminals of PHDA
neurons take up and store 5HT (86), but the role of this amine and other co-localized
neurotransmitters in the regulation of PHDA neurons and melanotroph hormone
secretion is unknown.
Neurochemistry
Concentrations
and rates of turnover of DA greatly exceed those of NE in the intermediate lobe
of the pituitary, the terminal region of PHDA neurons, so increases and decreases
in PHDA neuronal activity are reflected in concurrent changes in rates of DA
turnover and DOPA accumulation (36), and in concentrations of DOPAC in this
region (53). Changes in neurochemical
estimations of the activity of these neurons are reflected in changes in their
function. That is, increases and decreases
of PHDA neuronal activity are associated with decreases and increases, respectively,
in circulating concentrations of αMSH (52).
Regulation of Neuronal Activity
PHDA
neurons terminating in the intermediate lobe of the pituitary, unlike the anatomically-related
TIDA neurons, do not exhibit pronounced sexual differences, and are unresponsive
to changes in circulating levels of gonadal steroids (34).
On the other hand, PHDA neurons resemble the major ascending mestelencephalic
DA neurons in that they are regulated by DA receptor-mediated mechanisms. Acute administration of DA agonists and antagonists cause prompt
decreases and increases, respectively, of PHDA neuronal activity (75).
Putative afferent neurotransmitters
Agonists
and antagonists of mu (75) or delta
(68) opioid receptors do not alter PHDA neuronal activity. On the other hand, agonists and antagonists
of kappa opioid receptors decrease and increase, respectively, the activity
of PHDA neurons and cause reciprocal changes in circulating concentrations of
αMSH (62, 63). The ability of dynorphin
antibodies to mimic the stimulatory effects of kappa opioid antagonists on PHDA
neurons suggests that these neurons are inhibited tonically by an endogenous
dynorphin-containing neuronal system (67). Other peptides have stimulatory actions on
PHDA neurons; i.c.v. administration of bombesin, GRP (65) and neurotensin (77)
increase PHDA neuronal activity and cause concomittant decreases in concentration
of αMSH in plasma.
Neither
increasing activity at histaminergic receptors by i.c.v. administration of histamine
nor facilitating release of endogenous histamine influences basal PHDA activity;
neither do drugs that inhibit histamine synthesis or block histaminergic receptors
(22). Thus, while histaminergic neuronal
systems do not influence basal activity of PHDA neurons, they do play a role
in stress-induced inhibition of these neurons (see below).
Similarly, disruption of 5HT tranmission processes fails to alter basal
PHDA neuronal activity, but pharmacological activation of 5HT2 receptors
does reduce PHDA neuronal activity and increase αMSH secretion (29). Furthermore, 5HT neurons are involved in stress-induced
inhibition of PHDA neurons (30).
GABA,
a dominant inhibitory neurotransmitter in the hypothalamus, is co-localized
with DA in neurons innervating the posterior pituitary, and GABAA
and GABAB receptors are widely distributed in the hypothalamus. The activity of PHDA neurons is unaltered by
pharmacological manipulations of GABAA receptors, but the GABAB
receptor agonist baclofen reduces PHDA neuronal activity and increases circulating
concentrations of αMSH (31). Selective
GABAB antagonists block these effects of baclofen but have no effect
on PHDA neurons per se. This suggests that under basal conditions GABA
neurons are quiescent so that GABAA and GABAB receptors
are unoccupied and therefore unresponsive to the administration of GABA receptor
antagonists. GABA neurons, however,
are involved in the stress-induced inhibition of PHDA neurons (see below).
Stress
While
stressful manipulations activate mesolimbic and mesocortical DA neurons they
inhibit PHDA neurons and consequently increase secretion of αMSH from the
intermediate lobe of the pituitary (58). Results
of pharmacological studies suggest that neurons that transmit information by
histamine, 5HT and GABA all play a role in the response of PHDA neurons to stress.
Histaminergic
neurons are activated during stress and are involved in the stress-induced inhibition
of PHDA neurons; drugs that inhibit histamine synthesis or block H1
receptors attenuate the reduction of PHDA neuronal activity during stress (23).
5HT neurons also appear to be involved with stress-induced inhibition
of PHDA neurons since this response is blocked or attenuated in rats pretreated
with 5,7-dihydroxytryptamine to destroy 5HT neurons, with 8-hydroxy-2-(di-n-propylamino)-tetralin
to inhibit 5HT neuronal activity, and with 5HT2 receptor antagonists
(29). Since these pretreatments do not alter basal
activity of PHDA neurons it would appear that during non-stressful conditions
5HT neurons are quiescent, but become activated by stressful manipulations.
Since activation of 5HT2 receptors depolarizes and excites
postsynaptic membranes it is unlikely that 5HT neurons inhibit PHDA neurons
directly, but during stress act indirectly by activating inhibitory GABA interneurons.
Administration of 2-hydroxysaclofen, a GABAB antagonist, blocks
the inhibition of PHDA neurons and the secretion of αMSH resulting from
both the administration of a 5HT2 agonist and restraint stress (31).
In
summary, stressful manipulations activate a chain of neuronal events that are
translated into a hormonal response, the release of αMSH from melanotrophs
in the intermediate lobe of the pituitary.
This response is the result of two concurrent events: the release from
the adrenal medulla of epinephrine which, in turn, releases αMSH by activating
ß2 receptors on melanotrophs, and the removal of inhibitory tone
on the melanotroph exerted by PHDA neurons. Stress-induced inhibition of these neurons
appears to be mediated by histaminergic, 5HTergic and GABAergic neurons, the
latter two may be arranged in series. Thus,
it appears that PHDA neurons receive a convergence of inhibitory inputs which
are important for removing the tonic inhibition of melanotroph secretion during
stress.
INCERTOHYPOTHALAMIC
DOPAMINERGIC NEURONS
Anatomy
IHDA
neurons located in the most rostral portion of the MZI were originally described
as the A13 TH containing cell group by Dählström and Fuxe (12).
Perikarya of these densely packed DA neurons have extensive dendritic
processes oriented in the ventral plane which extend into the dorsomedial nucleus
of the hypothalamus (102). Early reports using glyoxylic acid histochemical
fluorescence techniques suggested that efferents of IHDA neurons project diffusely
into the surrounding anterior, dorsomedial and posterior regions of the hypothalamus
(9). The results of later neuroanatomical
(104) and neurochemical studies (19) revealed, however, that IHDA neurons project
to a variety of anatomically discrete brain regions including the central nucleus
of the amygdala, horizontal diagonal band of Broca, and hypothalamic paraventricular
nucleus. The results of recent tract tracing studies demonstrated that the
relative contribution of IHDA neurons to these regions varies; i.e. DA terminals
in the paraventricular nucleus originate exclusively from IHDA neurons in the
MZI, whereas IHDA neurons provide only a portion of the DA innervation of
the amygdala and horizontal diagonal band (11).
While
little information is available regarding the function of IHDA neurons, the
distribution of their axonal projections to divergent brain regions suggests
that these neurons may function in the integration of autonomic and neuroendocrine
responses to specific sensory stimuli. Indeed, IHDA neurons are located in the most rostral extent of the
zona incerta, a diencephalic region involved in processing afferent “sensory”
information and integrating efferent “motor” responses (60). This region receives input from a variety of
brain regions involved in sensory processing including the thalamus, hypothalamus,
and brain stem reticular formation, and has somatotopically arranged output
to all levels of the neuroaxis (84), including the limbic system and hypothalamus
(11, 104).
Neurochemistry
There
are two major considerations that should be made when using neurochemical techniques
to estimate IHDA neuronal activity. The
first of these is that IHDA neurons project to regions that are also innervated
by mesolimbic DA neurons, and accordingly, changes in DA neurochemistry within
these regions cannot be attributed exclusively to changes in IHDA neuronal activity.
Since a "pure" IHDA projection region has only been recently
identified, investigators have had to rely on neurochemical evaluation of changes
in the MZI, which contains soma, dendrites and possibly terminals of IHDA neurons,
and the dorsomedial nucleus (DMN) which is reported to contain dendrites and
some terminals of IHDA neurons.
A
second issue associated with biochemical estimation of DA neuronal activity
in the MZI and DMN is that these regions are densely innervated by NE neurons.
Using the tedious α-methyltyrosine technique DA and NE turnover
rates have been quantified (75), but DA turnover rates are not useful for determining
rapid and/or short-lasting changes in IHDA neuronal activity.
Following NSD 1015 administration DOPA accumulates in both DA and NE
neurons within the MZI and DMN so this technique is not useful for estimating
IHDA neuronal activity unless NE innervation to these regions has been eliminated.
With
some precautions, changes in concentrations of DOPAC and DA in the MZI and DMN
can be used to estimate changes in IHDA neuronal activity (97). DA is a precursor of NE, and as such is present
in low concentrations in NE neurons. When
impulse flow in NE neurons increases, TH is activated and the synthesis of DA
within NE neurons increases. Because
of limitations imposed by transport of DA into synaptic vesicles and/or the
activity of dopamine-ß-hydroxylase, which is located within these vesicles,
the concentration of DA within NE neurons increases, and some of the amine is
metabolized to DOPAC. Thus, a concurrent
increase in both DOPAC and DA concentrations within a region without a significant
change in the DOPAC/DA ratio is usually indicative of an increase in the activity
of NE neurons in this region. If this
is the case, the increase in DA and DOPAC will be accompanied by an increase
in the concentrations of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) a major
metabolite of NE. An increase in DOPAC
without a change in DA concentrations (i.e. increase in DOPAC/DA ratio) usually
signifies an increase in DA neuronal activity within a region.
In order to substantiate this conclusion it is advisable to determine
that concentrations of MHPG do not change and to measure DOPAC/DA ratios in
brains in which NE neurons have been destroyed by intracerebral injections of
6-hydroxydopamine (97).
Regulation of Neuronal Activity
IHDA
neurons are regulated by DA receptor-mediated mechanisms (75, 97) and in this
respect resemble neurons comprising the major ascending mesotelencephalic DA
systems. DA receptor agonists such as
apomorphine decrease, whereas DA receptor antagonists such as haloperidol increase
the activity of IHDA neurons (75, 97). In addition, local application of DA inhibits the firing rate of
neurons in the MZI possibly by activating autoreceptors on A13 DA
perikarya or dendrites (16, 87). These
effects are likely mediated by D3 (or possibly a subtype of D2)
DA receptors since IHDA neurons are responsive to the mixed D2/D3
antagonist raclopride, but not the selective D2 antagonist remoxipride
(17).
IHDA
neurons are activated following acute administration of morphine by a mechanism
involving mu opioid receptors (75, 97). Activation
of kappa opioid receptors has no effect on the activity of IHDA neurons (97).
The stimulatory effects of mu opioid receptor activation on IHDA neurons
are not dependent upon the presence of 5HT neurons since neurotoxin-induced
disruption of 5HT innervation to the hypothalamus does not alter the abililty
of morphine to stimulate the activity of IHDA neurons (97).
In this respect, IHDA neurons resemble extrahypothalamic mesotelencephalic
DA neurons rather than hypothalamic TIDA neurons.
Another
difference between IHDA and TIDA neurons is that IHDA neurons are not responsive
to experimentally-induced changes in circulating levels of gonadal steroids
or prolactin. There is no sexual difference
in the basal activity of IHDA neurons, and neither castration nor steroid hormone
treatment alters the activity of IHDA neurons (35) or TH gene expression in
the MZI of either gender (76, 90). Furthermore, IHDA neurons in the MZI are not responsive to chronic
elevations in prolactin concentrations (2, 75, 90) suggesting that these neurons
are not involved in the regulation of basal prolactin secretion and do not mediate
the effects of hyperprolactinemia on reproductive function.
Although
IHDA neurons are unresponsive to hormonal feedback regulation they have been
reported to stimulate the preovulatory surge of luteinizing hormone and ovulation
(61, 88). Direct injection of DA or
its agonists into the MZI increases luteinizing hormone secretion and causes
ovulation by a mechanism involving D1 receptors (45, 61).
Conversely, lesions of the MZI block the proestrous surge of luteinizing
hormone (88) and disrupts estrous cyclicity (61).
The role of efferent projections of IHDA to the horizontal diagonal band
of Broca, a region containing gonadotropin releasing hormone perikarya, in regulating
preovulatory surges of luteinizing hormone remains to be elucidated.
Elucidation
of the function of IHDA neurons has been hampered by the paucity of information
on the anatomical location of their axonal projections, but the recent identification
of the hypothalamic paraventricular nucleus as a brain region which receives
its DA innervation from the MZI suggests a role for IHDA neurons in the regulation
of neurosecretory neurons located in this region. Indeed, pharmacological activation of D1
and D2 DA receptors stimulates gene expression in corticotropin-releasing
hormone (CRH) neurons in the paraventricular nucleus (20) suggesting that IHDA
neurons participate in neuronal regulation of the hypothalamic-pituitary-adrenal
axis. That central CRH administration
increases the metabolism of DA in the paraventricular nucleus (78) suggests
that CRH neurons may, in turn, regulate the activity of IHDA neurons projecting
to this region.
PERIVENTRICULAR
DOPAMINERGIC NEURONS
Anatomy
Perikarya
of A14 PeVDA neurons are distributed in the periventricular nucleus
throughout the entire rostrocaudal extent of the third ventricle (102). Dendrites of these neurons are oriented in
the dorsoventral plane and overlap extensively with dendrites from adjacent
DA neurons. PeVDA perikarya are also
distributed laterally along the ventral surface of the brain near the supraoptic
and suprachiasmatic nuclei (102). In
the rostroventral region of the periventricular nucleus, the distribution of
PeVDA neurons is sexually dimorphic in that the number of TH immunoreactive
cells and fibers is 2 to 3-fold higher in females than in males (93).
Although little information is available regarding the efferent projections
of PeVDA neurons, fibers of these neurons in the rostral periventricular nucleus
extend laterally into the adjacent medial preoptic nucleus and anterior hypothalamic
area (9).
A
number of neuropeptides including neurotensin (43), cholecystokinin, and vasoactive
intestine polypeptide (91) are co-localized with DA in the periventricular nucleus,
but little information is available regarding the effects of these neurotransmitters
on the activity or function of PeVDA neurons.
Neurochemistry
Comments
on neurochemical estimation of the activity of IHDA neurons (see above) are
also pertinent for PeVDA neurons. Thus,
unless activated NE neurons contribute significantly to tissue concentrations
of DOPAC and DA, changes in concentrations of DOPAC and DA in the medial preoptic
nucleus and anterior hypothalamic area can be used to estimate changes in PeVDA
neuronal activity (97).
Regulation of Neuronal Activity
PeVDA
neurons are regulated by DA receptor-mediated mechanisms and in this respect
resemble IHDA neurons in the MZI (75). Acute
administration of DA receptor antagonists and agonists increase and decrease,
respectively, the activity of DA neurons in the periventricular nucleus and
adjacent medial preoptic nucleus and anterior hypothalamic area. Furthermore, inhibition of neuronal activity
following administration of gamma-hydroxybutyrolactone results in an apomorphine-reversible
increase in DA concentrations in these regions suggesting that PeVDA neurons
are regulated, at least in part, by DA autoreceptors located on dendrites, perikarya
and/or axon terminals of these neurons (75).
PeVDA
neurons in the rostral periventricular nucleus and medial preoptic nucleus are
activated following acute administration of morphine by a mechanism involving
mu opioid receptors (75). No information
is available regarding the effects of kappa or delta opioid receptor activation
or blockade on the activity of these neurons.
In
contrast to IHDA neurons, PeVDA neurons in the rostral hypothalamus are responsive
to experimentally-induced changes in circulating levels of gonadal steroids
and prolactin. There is a sexual difference
in the basal activity of PeVDA neurons projecting to the rostral, periventricular
and medial preoptic nuclei with the activity in females being 20-30% higher
than males (35). This sexual difference
in the activity of PeVDA neurons in the medial preoptic nucleus could be due,
in part, to the inhibitory effects of testosterone in males (94), and/or the
stimulatory effects of estrogen in females (75).
Testosterone treatment of orchidectomized males has also been reported
to have a stimulatory effect on the activity of PeVDA neurons in the medial
preoptic area (35). Experimental manipulations which produce elevations
in circulating prolactin decrease the activity of DA neurons in the medial preoptic
area of gonadally-intact males (75), and counteract the inhibitory effects of
testosterone on these neurons in orchidectomized males (47).
Although
the function of PeVDA neurons is currently unknown, compelling evidence suggests
that those neurons terminating in the medial preoptic area are important in
regulating male sexual behavior. Indeed,
neurotoxin-induced lesions of DA neurons in the medial preoptic nucleus (6)
or direct injection of a DA antagonist into this region (80) decreases male
copulatory behavior by a mechanism involving D2 DA receptor regulation
of reflexive and motivational factors, rather than locomotion (111).
This is supported by the observation that DA neuronal activity is increased
in the medial preoptic area in males during copulation (42).
In females, DA neurons in the medial preoptic area have been implicated
in the regulation estrogen-induced sexual receptivity (112) and in the desensitization
of the negative feedback effect of estrogen on luteinizing hormone secretion
that occurs during puberty (13).
HYPOTHALAMIC
DOPAMINERGIC NEURONS IN THE HUMAN
Information
on hypothalamic DA neurons provided above has been obtained primarily from studies
conducted in the rat. There have been
relatively few studies on DA neurons in the human brain and the majority of
these, as in the rat, have focused on those DA neurons that comprise the nigrostriatal,
mesolimbic and mesocortical systems. Functional studies in humans have revealed
that drugs that disrupt DA synthesis or block D2 DA receptors increase
circulating concentrations of prolactin. This suggests that, as in the rat, the secretion of prolactin is
tonically inhibited by DA released from neurons terminating near the primary
capillary loops of the hypophysial portal system.
Spencer
et al. (95) were the first to map TH-immunoreactive neurons in the male adult
human hypothalamus; they noted positive staining cells in the paraventricular,
supraoptic, periventricular and arcuate nuclei, and in the dorsal lateral hypothalamus
(the latter 3 regions correspond to A14, A12 and A13
regions in the rat, respectively). Since
TH staining neurons in the human hypothalamus are not immunoreactive to dopamine
β-hydroxylase antiserum it is assumed they are DA (24).
Using improved immunohistochemical procedures Li et al. (50) and Panaytacoupoulou
et al. (79) demonstrated that in the hypothalamus of developing human brain
the majority of TH-containing neurons were located in the paraventricular and
supraoptic nuclei. Up to 40% of the
magnocellular neurons within these two nuclei contained TH and in many of these
neurons this enzyme was colocalized with either vasopressin or oxytocin. This contrasts to the mouse, rat and rabbit
where only a small number of magnocellular neurons in the paraventricular and
supraoptic nuclei contain TH (102). It
is interesting, however, that dehydration and hyperosmotic stimuli in the rat
increase TH mRNA in magnocellular neurons (113), and this may be the reason
for the increased concentration and rate of synthesis of dopamine in terminal
regions of these neurons in the posterior pituitary of rats subjected to dehydration
or salt loading (see PHDA; 75)
Patients
suffering from Parkinson’s disease do not exhibit elevated plasma levels of
prolactin suggesting that TIDA neurons remain functional in these patients.
Furthermore, postmortem analyses of parkinsonian
brains revealed that, in contrast to the marked loss of dopaminergic neurons
in the substantia nigra, there was no loss of TH immunoreactive neurons in the
supraoptic, paraventricular, periventricular or arcuate nuclei (87).
It appears, therefore, that hypothalamic dopaminergic neurons do not
degenerate in Parkinson’s disease but the reason for their resistance to degeneration
does not appear to be the presence of calbindin-D28K because this calcium binding
protein that protects neurons from degenerating is colocalized with only a small
number of hypothalamic dopaminergic neurons (89).
There
is no evidence to support the existence in humans of a DA neuronal system comparable
to PHDA neurons in the rat. A distinct
intermediate lobe is present in human fetal and neonatal pituitaries, but the
size of this lobe diminishes with age so that in the adult there is no well-defined
intermediate lobe. Although melanotrophs
are dispersed throughout the human anterior pituitary it is not known if these
cells are innervated by DA neurons or if they respond to the administration
of DA agonists and antagonists. As noted above, little is known about the functions of A13
and rostral A14 DA cell bodies in the rat, and there have been no
studies on comparable neurons in the human brain.
A
review of hypothalamic DA neurons published in the last volume of Psychopharmacology:
The Third Generation of Progress (75) focused primarily on TIDA neurons that
tonically inhibit the secretion of prolactin from the anterior pituitary.
It was noted that many properties of these DA neurons are distinctly
different from those of the major ascending nigrostriatal and mesolimbic DA
neuronal systems. Although the importance of the hormonal regulation
of TIDA neurons was emphasized it was also recognized that these neurons respond
acutely to sensory stimuli, but the chemical characteristics of afferent neurons
that influence TIDA neurons was largely unknown at that time. Since 1987 the characteristic responses of
TIDA neurons to putative neurotransmitters, and to compounds that mimic the
actions of these transmitters have been documented and reviewed here.
New
information has also been included regarding activity-related regulation of
gene expression in TIDA neurons which results in synthesis of enzymes important
for the maintenance of DA synthesis and the ability of these neurons to respond
to chronic stimulation.
Over
the past few years much has been learned about the hypothalamic DA neurons that
innervate the intermediate lobe of the pituitary. These PHDA neurons, unlike TIDA neurons, are not responsive to changes
in hormonal milieu, but are inhibited by stress and are activated or inhibited
by a variety of compounds that interfere with or mimic the actions of aminergic
or peptidergic neurotransmitters.
Studies
on the mechanisms by which TIDA and PHDA neurons are regulated have been assisted
greatly by knowledge of the anatomical distribution and functions of these neurons.
Until recently, this has not been the case with IHDA or PeVDA neurons.
The finding that IHDA neurons have discrete projection sites in the horizontal
band and hypothalamic paraventicular nucleus should lead to the elucidation
of the role these neurons play in regulating neurosecretory neurons located
in these regions. The endocrinological consequences of psychoactive drugs that
mimic, facilitate or block DA neurotransmission of TIDA and PHDA neurons are
well recognized. The challenge now is
to characterize further the functions of the IHDA and PeVDA neurons.
Only then will it be possible to evaluate potential therapeutic or adverse
effects of pharmacological manipulations that modify these two, as yet poorly
understood, hypothalamic DA systems.
The
authors' studies cited in this review were supported by NIH grants NS15911 and
MH42802.
published 2000